Radiation therapy for preventing instrumentation track metastases in malignant pleural mesothelioma
Información
- DOI:
- https://doi.org/10.1002/14651858.CD012541Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 02 febrero 2017see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Protocol
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Cáncer de pulmón
- Copyright:
-
- Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
JE wrote the review protocol. JB, RB, IY and KF provided editorial and methodological support.
Declarations of interest
Jacques G Eastment, Joseph P Burke and Rayleen Bowman have no conflicts of interest
Associate Professor I Yang
Dr Yang is an employee of Metro North Hospital and Health Service and The University of Queensland.
Dr Yang declares that he has not received consultancy fees or honoraria from pharmaceutical companies, and has not acted as a member of advisory boards for pharmaceutical companies.
Dr Yang declares that in the last 3 years, he has:
‐Given COPD presentations (all his own slides) at educational meetings organised by pharmaceutical companies (Boehringer Ingelheim, Novartis, AstraZeneca, Menarini) � in all instances, he donated the honorarium, if any.
‐Accepted hospitality in connection with attending evening professional educational meetings organised by pharmaceutical companies.
Dr Yang is Chair of the National COPD Guidelines Committee of the Lung Foundation Australia (http://lungfoundation.com.au/). This not‐for‐profit public benevolent institution which receives grant support from pharmaceutical and other industry companies (Boehringer Ingelheim, Novartis, GSK, AstraZeneca, Air Liquide, Menarini) towards its National COPD Program.
Dr Yang is a Board member of the Asthma Foundation Queensland NSW.
He is on the editorial boards of the following international journals: Respirology, Annals of the American Thoracic Society and the Cochrane Airways Group.
Professor K Fung
Professor Fong is a contributor to the Australian national mesothelioma clinical guidelines, currently being drafted.
He has received conference support for speaking at various educational meetings from Organisers of meetings which include not‐for‐profits and industry ‐ only travel expenses claimed (2014APLCC Roche Symposium (Kuala Lumpur) Chair and Speaker
2017 Astra Zeneca NRLS meeting (Sydney)
He was member on the Board for the International Association for the Study of Lung Cancer ‐ also on the Executive of the Asian Pacific Society of Respirology ‐ some travel expenses reimbursed. Chair Lung Foundation Australia Lung Cancer Consultative Group ‐ travel expenses reimbursed.
He was reimbursed for time in critically reviewing grant applications for a state cancer agency, and honoraria for time to mark higher degree theses.
Pr. Fong was reimbursed for time in critically reviewing grant applications for a state cancer agency, and honoraria for time to mark higher degree theses.
Grants paid to his institution: NHMRC, Hospital Foundation, Cancer Australia, Cancer Council Queensland
Acknowledgements
We thank Corynne Marchal, the Managing Editor of the Cochrane Lung Cancer Group, for her guidance in drafting the review protocol. We also acknowledge the following members of the Cochrane Lung Cancer Group for their peer reviews: Desiree West, David Ball, Ivan Sola, Noelle O'Rourke, Sophie Paget‐Bailly.
Version history
| Published | Title | Stage | Authors | Version |
| 2017 Feb 02 | Radiation therapy for preventing instrumentation track metastases in malignant pleural mesothelioma | Protocol | Jacques G Eastment, Joseph P Burke, Kwun M Fong, Ian A Yang, Rayleen V Bowman | |
